Skip to main content

Pfizer Inc.

corporate_fare Company Profile

Pfizer Inc.

PFE·NYSE·Life Sciences·CIK 0000078003

Pfizer Inc. is a research-based, global biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes biopharmaceutical products worldwide. The company applies science and global resources to provide therapies that extend and significantly improve lives. Pfizer operates in both developed and emerging markets, focusing on wellness, prevention, treatments, and cures for significant diseases. It collaborates with healthcare providers, governments, and local communities to support and expand access to reliable, affordable healthcare globally. Incorporated in Delaware on June 2, 1942, Pfizer generates most of its revenues from the manufacture and sale of biopharmaceutical products. The company aims to enhance the value of its medicines and vaccines and works with patients, physicians, and payors to prevent and treat disease and improve outcomes. Pfizer evaluates its pricing arrangements and contracting methods with payors to maximize patient access while minimizing adverse impacts on revenues within current legal and pricing structures.

Pfizer Inc. (NYSE:PFE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 67 items for PFE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for PFE spans 8-K, 10-Q.

Recent high-impact activity:

  • Pfizer Pays $330M Upfront for Starna's In Vivo CAR-T Autoimmune Pipeline
  • Padcev-Imfinzi Cuts Bladder Cancer Death Risk 42%; Blackstone Backs Obesity Drug With $1.5B
  • FDA Clears Durvalumab-Enfortumab Combo for Muscle Invasive Bladder Cancer
  • Blackstone to Fund Up to $1.5B of Pfizer's Monthly GLP-1 Obesity Drug Through 2028
  • Pfizer Beats on Q3, Raises 2026 Revenue Guidance to $62-64B and EPS to $2.95-$3.05

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$62.58B
Net Income
$7.77B
Diluted EPS
$1.36
Op. Cash Flow
$11.7B
Free Cash Flow
$9.07B
Gross Profit
$46.51B
Cash & Equivalents
$1.14B
Total Debt
$64.64B
Debt / Equity
0.75×
Net Margin
12.4%
Shares Outstanding
5.68B sh
Source: 10-K · filed 2026-02-26 · accession 0000078003-26-000026

Short Interest & Short Volume

4.58 days to cover

FINRA reported short interest of 134,422,620 shares in PFE as of the October 30, 2026 settlement, a 2.5% decrease from the prior period — about 4.6 days to cover at its recent average daily volume. On November 20, 2026, 34.1% of PFE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)134,422,620 shares as of October 30, 2026
Change vs prior period▼ 2.5%
Days to cover4.58 at avg daily volume of 29,322,354
Daily short volume (FINRA facilities)34.1% of 13,068,139 shares on November 20, 2026
5-day average short volume31.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$27.44 +0.15% today
52-week range · as of 2026-11-03 $23.62 – $31.04
Market cap
$156.18B
Volume
38.3M (1.1× avg)
3-mo avg 34.6M
Live data · 2026-11-21 15:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PFE - Latest Insights

PFE
Nov 18, 2026, 7:20 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Updated Nov 18, 11:56 AM ET — Pfizer's Starna deal gives it exclusive rights outside Greater China to three in vivo CAR-T programs, plus options to license compounds fro…
Price at Filing: $28.28
Real-time Price: $27.44 info
Change: -$0.840 (-3%) info
Market Cap: $156.176B info
PFE
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.12
Real-time Price: $27.44 info
Change: -$1.68 (-6%) info
Market Cap: $156.176B info
PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $27.44 info
Change: -$1.41 (-5%) info
Market Cap: $156.176B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $27.44 info
Change: -$2.01 (-7%) info
Market Cap: $156.176B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Updated Nov 3, 12:27 PM ET — Pfizer's Q3 non-COVID portfolio grew 7% operationally, with Eliquis sales up 25% to $2.52 billion and Padcev up 55% to $720 million; shares…
Price at Filing: $30.62
Real-time Price: $27.44 info
Change: -$3.18 (-10%) info
Market Cap: $156.176B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $27.44 info
Change: -$3.22 (-11%) info
Market Cap: $156.176B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $27.44 info
Change: -$3.29 (-11%) info
Market Cap: $156.176B info
PFE
Nov 03, 2026, 6:45 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Updated Nov 3, 6:53 AM ET — Pfizer's Q3 revenue of $16.58 bln beat the $15.87 bln consensus and adjusted EPS of $0.87 beat $0.73; 2026 adjusted EPS guidance is $2.95-$…
Price at Filing: $30.98
Real-time Price: $27.44 info
Change: -$3.54 (-11%) info
Market Cap: $156.176B info
PFE
Oct 27, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.77
Real-time Price: $27.44 info
Change: -$2.33 (-8%) info
Market Cap: $156.176B info
PFE
Oct 26, 2026, 2:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $29.82
Real-time Price: $27.44 info
Change: -$2.38 (-8%) info
Market Cap: $156.176B info
PFE
Oct 13, 2026, 7:09 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $28.60
Real-time Price: $27.44 info
Change: -$1.16 (-4%) info
Market Cap: $156.176B info
PFE
Oct 12, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.36
Real-time Price: $27.44 info
Change: -$0.920 (-3%) info
Market Cap: $156.176B info
PFE
Oct 07, 2026, 12:57 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $28.07
Real-time Price: $27.44 info
Change: -$0.625 (-2%) info
Market Cap: $156.176B info
PFE
Oct 02, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Updated Oct 5, 3:59 PM ET — The lawsuit alleges Pfizer spent over $10 billion on advertising from 2020 to 2023, generating over $80 billion in vaccine sales, and that…
Price at Filing: $28.12
Real-time Price: $27.44 info
Change: -$0.6795 (-2%) info
Market Cap: $156.176B info
PFE
Oct 02, 2026, 11:15 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $27.72
Real-time Price: $27.44 info
Change: -$0.2751 (-0.99%) info
Market Cap: $156.176B info
PFE
Oct 01, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $28.32
Real-time Price: $27.44 info
Change: -$0.875 (-3%) info
Market Cap: $156.176B info
PFE
Oct 01, 2026, 2:30 AM EDT
Source: BusinessWire
Importance Score:
8
Updated Oct 1, 7:12 AM ET — Detailed data showed up to 62.5% achieved EASI-75, with statistically significant increases across all doses vs placebo at Week 16.
Price at Filing: $28.59
Real-time Price: $27.44 info
Change: -$1.15 (-4%) info
Market Cap: $156.176B info
PFE
Oct 01, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.59
Real-time Price: $27.44 info
Change: -$1.15 (-4%) info
Market Cap: $156.176B info
PFE
Sep 21, 2026, 2:15 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $27.62
Real-time Price: $27.44 info
Change: -$0.180 (-0.65%) info
Market Cap: $156.176B info
PFE
Sep 07, 2026, 2:46 AM EDT
Source: CNBC TV18
Importance Score:
7
Price at Filing: $28.44
Real-time Price: $27.44 info
Change: -$1.00 (-4%) info
Market Cap: $156.176B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets